At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Comprehensive Ototoxicity Monitoring Program for VA: A Randomized Trial
In Brief
A clinical study evaluating COMP-VA and Standard of care for Cisplatin Ototoxicity and Hearing Loss. Completed, enrolled 47 participants across 1 site.
Detailed Summary
This study involves research. Some chemotherapeutic drugs that can permanently reduce hearing are termed "ototoxic". One such drug is the chemotherapy called cisplatin. Currently, if a patient is receiving cisplatin, hearing is tested in the Audiology Clinic using lengthy protocols and may be retested only when it is requested by their oncologist and when the Veteran can arrange an appointment. Researchers think that hearing testing prior to every treatment of cisplatin may reduce the number of Veterans who get disabling hearing loss from treatment. The purpose of this study is to compare the current method of monitoring hearing (audiology clinic protocols termed "usual care") with a new portable hearing monitoring program (a comprehensive program of ototoxicity monitoring termed "COMP-VA") that tests hearing using a portable hearing testing audiometer and a variety of efficient tools and techniques so that testing can occur prior to each cisplatin treatment at any quiet location in the hospital.
Study Details
Timeline
Interventions
Hearing testing at each treatment interval by the comp-va audiologist
Hearing testing done in the audiology clinic after oncology referral or patient self referral